Vifor Confident About Veltassa Despite AZ Rival
Hyperkalemia Therapy Now Has Competition From Lokelma
The Swiss company has been talking up its therapy for elevated levels of potassium in the blood which contributed to strong sales growth for Vifor in 2019.
You may also be interested in...
Though the policy environment can be 'uncertain,' AstraZeneca has 'good grasp' on how the anemia drug for patients with chronic kidney disease will be covered under the Medicare end-stage renal disease bundled payment system, senior VP for market access Rick Suarez says.
Patients with high levels of blood potassium in England have two more options for treating their condition after NICE reversed its earlier negative recommendations.
Competition intensifies in novel anemia therapy space in Japan with first filing globally for Akebia/Mitsubishi Tanabe’s contender vadadustat, which could see its first launch worldwide in the country.